FXN and Friedreich ataxia: Treatment with antisense oligonucleotides (ASOs) covering intronic splicing regulator motifs resulted in increased FXN expression from the point mutation allele in Friedreich’s ataxia fibroblasts and from a miniFXN gene carrying the same mutation.